Authors
Loading...
Phase II trial shows CART–ASCT–CART2 regimen improves outcomes in primary plasma cell leukemia, indicating potential benefits over previous therapies.
Xu et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: